Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells.
Paradoxically, cancer resistance to certain therapies can be exploited for protection of …

Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression of metastatic
breast cancer. However, complete responses are uncommon and tumors eventually relapse …

Cancer therapies trigger diverse cellular responses, ranging from apoptotic death to
acquisition of persistent therapy-refractory states such as senescence. Tipping the balance …

Intrinsic resistance of unknown mechanism impedes the clinical utility of inhibitors of cyclin-
dependent kinases 4 and 6 (CDK4/6i) in malignancies other than breast cancer. Here, we …

Melanomas and their precursors, the melanocytes, are frequently exposed to UV due to their
anatomic location, leading to DNA damage and reactive oxygen stress related harm. Such …

Chronic lymphocytic leukemia (CLL) is a genetically and clinically diverse hematological
cancer affecting middle-aged and elderly individuals. Novel targeted therapy options are …

Fluoride overexposure is an environmental health hazard and can cause enamel and
skeletal fluorosis. Previously we demonstrated that fluoride increased acetylated-p53 and its …

Targeting MDM2-p53 interaction has emerged as a promising antitumor therapeutic
strategy. Several MDM2-p53 inhibitors have advanced into clinical trials, but results are not …

Human breast cancer is characterized by a high degree of inter-patients heterogeneity in
terms of histology, genomic alterations, gene expression patterns, and metastatic behavior …

Genetically identical cells can respond heterogeneously to cancer therapy, with a
subpopulation of cells often entering a temporarily arrested treatment-tolerant state before …